WO1996020160A1 - 1,3,3-(trisubstituted)cyclohexane dimers and related compounds - Google Patents

1,3,3-(trisubstituted)cyclohexane dimers and related compounds Download PDF

Info

Publication number
WO1996020160A1
WO1996020160A1 PCT/US1995/013267 US9513267W WO9620160A1 WO 1996020160 A1 WO1996020160 A1 WO 1996020160A1 US 9513267 W US9513267 W US 9513267W WO 9620160 A1 WO9620160 A1 WO 9620160A1
Authority
WO
WIPO (PCT)
Prior art keywords
cr8r8
independently selected
cr4r5
alkyl
hydrogen
Prior art date
Application number
PCT/US1995/013267
Other languages
French (fr)
Inventor
Siegfried B. Christensen, Iv
Joseph M. Karpinski
Original Assignee
Smithkline Beecham Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corporation filed Critical Smithkline Beecham Corporation
Priority to EP95938251A priority Critical patent/EP0799185A4/en
Priority to JP8520430A priority patent/JPH10511387A/en
Publication of WO1996020160A1 publication Critical patent/WO1996020160A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C61/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C61/16—Unsaturated compounds
    • C07C61/39—Unsaturated compounds containing six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/74—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/235—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring and to a carbon atom of a ring other than a six-membered aromatic ring
    • C07C43/253—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring and to a carbon atom of a ring other than a six-membered aromatic ring containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C61/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C61/16—Unsaturated compounds
    • C07C61/40—Unsaturated compounds containing halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Definitions

  • the present invention relates to novel l,3,3-(trisubstituted)cyclohexane dimers and related compounds, pharmaceutical compositions containing these compounds, and their use in treating allergic and inflammatory diseases and for inhibiting the production of Tumor Necrosis Factor (TNF).
  • TNF Tumor Necrosis Factor
  • Bronchial asthma is a complex, multifactorial disease characterized by reversible narrowing of the airway and hyperreactivity of the respiratory tract to external stimuli.
  • Cyclic AMP adenosine cyclic 3',5'- monophosphate
  • Cyclic AMP has been shown to be a second messenger mediating the biologic responses to a wide range of hormones, neurotransmitters and drugs; [Krebs Endocrinology Proceedings of the 4th International Congress Excerpta Medica, 17-29, 1973].
  • adenylate cyclase is activated, which converts Mg + * ⁇ -ATP to cAMP at an accelerated rate.
  • Cyclic AMP modulates the activity of most, if not all, of the cells that contribute to the pathophysiology of extrinsic (allergic) asthma.
  • an elevation of c AMP would produce beneficial effects including: 1) airway smooth muscle relaxation, 2) inhibition of mast cell mediator release, 3) suppression of neutrophil degranulation, 4) inhibition of basophil degranulation, and 5) inhibition of monocytc and macrophage activation.
  • compounds that activate adenylate cyclase or inhibit phosphodiesterase should be effective in suppressing the inappropriate activation of airway smooth muscle and a wide variety of inflammatory cells.
  • the principal cellular mechanism for the inactivation of cAMP is hydrolysis of the 3'- phosphodiester bond by one or more of a family of isozymes referred to as cyclic nucleotide phosphodiesterases (PDEs).
  • PDE IV cyclic nucleotide phosphodiesterase
  • PDE IV inhibitors are markedly potentiated when adenylate cyclase activity of target cells is elevated by appropriate hormones or autocoids, as would be the case in vivo.
  • PDE IV inhibitors would be effective in the asthmatic lung, where levels of prostaglandin E2 and prostacyclin (activators of adenylate cyclase) are elevated.
  • Such compounds would offer a unique approach toward the pharmacotherapy of bronchial asthma and possess significant therapeutic advantages over agents currently on the market.
  • TNF Tumor Necrosis Factor
  • rheumatoid arthritis rheumatoid spondylitis, ostectarthri ⁇ s, gouty arthritis and other arthritic conditions
  • sepsis septic shock, endotoxic shock, gram negative sepsis, toxic shock syndrome, adult respiratory distress syndrome, cerebral malaria, chronic pulmonary inflammatory disease, silicosis, pulmonary sarcoidosis, bone resorption diseases, reperfusion injury, graft vs. host reaction, allograft rejections, fever and myalgias due to infection, such as influenza, cachexia secondary to infection or malignancy, cachexia secondary to human acquired immune deficiency syndrome
  • TNF Tumor Necrosis Factor
  • AIDS AIDS
  • AIDS AIDS
  • ARC AIDS related complex
  • keloid formation scar tissue formation
  • Crohn's disease Crohn's disease
  • ulcerative colitis or pyresis
  • AIDS results from the infection of T lymphocytes with Human
  • HTV Immunodeficiency Virus
  • HIV-1 HIV-1
  • HIV-2 HIV-2
  • HIV-3 HIV-3
  • HIV entry into the T lymphocyte requires T lymphocyte activation.
  • Viruses such as HTV- 1 or HTV-2 infect T lymphocytes after T cell activation and such virus protein expression and/or replication is mediated or maintained by such T cell activation. Once an activated T lymphocyte is infected with HIV, the T lymphocyte must continue to be maintained in an activated state to permit HIV gene expression and/or HTV replication.
  • Cytokines are implicated in activated T-cell-mediated HTV protein expression and/or virus replication by playing a role in maintaining T lymphocyte activation. Therefore, interference with cytokine activity such as by inhibition of cytokine production, notably TNF, in an HTV-infected individual aids in limiting the maintenance of T cell activation, thereby reducing the progression of HTV infectivity to previously uninfected cells which results in a slowing or elimination of the progression of immune dysfunction caused by HTV infection.
  • Monocytes, macrophages, and related cells, such as kupffer and glial cells have also been implicated in maintenance of the HTV infection.
  • T cells like T cells, are targets for viral replication and the level of viral replication is dependent upon the activation state of the cells.
  • Monokines such as TNF, have been shown to activate HTV replication in monocytes and or macrophages [See Poli et al., Proc. Natl. Acad. Sci., 87:782-784, 1990], therefore, inhibition of monokine production or activity aids in limiting HTV progression as stated above for T cells.
  • TNF has also been implicated in various roles with other viral infections, such as the cytomegalovirus (CMV), influenza virus, adenovirus, and the herpes virus for similar reasons as those noted.
  • CMV cytomegalovirus
  • influenza virus influenza virus
  • adenovirus adenovirus
  • herpes virus herpes virus
  • TNF is also associated with yeast and fungal infections. Specifically Candida albicans has been shown to induce TNF production in vitro in human monocytes and natural killer cells. [See Riipi et al, Infection and Immunity, 58(9):2750-54, 1990; and Jafari et al, Journal of Infectious Diseases, 164:389-95, 1991. See also Wasan et al, Antimicrobial Agents and Chemotherapy, 35,(10):2046-48, 1991; and Luke et al, Journal of Infectious Diseases, 162:211-214,1990]. The ability to control the adverse effects of TNF is furthered by the use of the compounds which inhibit TNF in mammals who are in need of such use. There remains a need for compounds which are useful in treating TNF-mediated disease states which are exacerbated or caused by the excessive and/or unregulated production of TNF. Summary of the Invention
  • Rl is independently selected from -(CR4R5)nC(O)O(CR4R5)mR6,
  • R4 and R5 are independently selected from hydrogen or Ci-2 alkyl;
  • R6 is independently selected from hydrogen, methyl, hydroxyl, aryl, halo substituted aryl, aryloxyCi-3 alkyl, halo substituted aryloxyCl-3 alkyl, indanyl, indenyl, C7-11 polycycloalkyl, tetrahydrofuranyl, furanyl, tetrahydropyranyl, pyranyl, tetrahydrothienyl, thienyl, tetrahydrothiopyranyl, thiopyranyl, C3-6 cycloalkyl, or a C4- 6 cycloalkyl containing one or two unsaturated bonds, wherein the cycloalkyl or heterocyclic moiety is unsubstituted or substituted by 1 to 3 methyl groups, one ethyl group, or an hydroxyl group; provided that: a) when R6 is hydroxyl, then
  • X is independently selected from YR2, fluorine, NR4R5, or formyl amine;
  • Y is independently selected from O or S(O)m'; m' is O, l, or 2;
  • X2 is independently selected from O or NR8;
  • X3 is independently selected from hydrogen or X; R2 is independently selected from the group consisting of -CH3 and -CH2CH3 optionally substituted by 1 or more fluorines; s is 0 to 4; W is alkyl of 2 to 6 carbons, alkenyl of 2 to 6 carbon atoms or alkynyl of 2 to 6 carbon atoms; Z is independently CR8R8OR14, CR8 8OR15, CR ⁇ ⁇ SR , CR8R8SR15,
  • CR8R8NRl ⁇ C(NRlO)SR9 CR8R8NRl ⁇ C(NRlO)NRi()Ri4, CR8R8NRl ⁇ C(O)C(O)NR ⁇ oRl4, or CR8R8NRl ⁇ C(O)C(O)ORi4;
  • X5 is H, R9, OR8, CN, C(O)R8, C(O)OR8, C(O)NR8R8, or NR8R8;
  • X4 is independently H, R9, OR8, CN, C(O)R8, C(O)OR8, C(O)NRsR8, or
  • Y' is independently selected from O or S;
  • R7 is -(CR4R5) ⁇ Ri2 or Cj. ⁇ alkyl wherein the Rl2 or Cj.g alkyl group is unsubstituted or substituted one or more times by methyl or ethyl unsubstituted or substituted by 1-3 fluorines, -F, -Br, -Cl, -NO2, -NRioRl 1* -C(0)R8, -CO2R8, -O(CH 2 ) q R8, -CN, -C(O)NR ⁇ oRl l, -O(CH 2 ) q C(O)NRl ⁇ Rl l, -O(CH 2 ) q C(O)R9, -NR ⁇ oC(O)NR ⁇ oRl l, -NRl ⁇ C(O)Rn, -NR ⁇ oC(O)OR9, -NR ⁇ oC(O)Ri3, -C(NRi ⁇ )NRl ⁇ Rl l,
  • Rl2 is independently selected from R13, C3.7 cycloalkyl, (2-, 3- or 4-pyridyl), pyrimidyl, pyrazolyl, (1- or 2-imidazolyl), pyirolyl, piperazinyl, piperidinyl, mo holinyl, furanyl, (2- or 3-thienyl), quinolinyl, naphthyl, or phenyl; R is independently selected from hydrogen or R9;
  • R9 is independently selected from C1.4 alkyl optionally substituted by one to three fluorines
  • RjO is independently selected from OR8 or Ri 1;
  • R ⁇ i is independently selected from hydrogen, or C 1.4 alkyl optionally substituted by one to three fluorines; or when R10 and Ri l are as NRioRl 1 they may together with the nitrogen form a 5 to 7 membered ring comprised of carbon or carbon and at least one additional heteroatom selected from O, N, or S;
  • Rl3 is independently selected from oxazolidinyl, oxazolyl, thiazolyl, pyrazolyl, triazolyl, tetrazolyl, imidazolyl, imidazolidinyl, thiazolidinyl, isoxazolyl, oxadiazolyl, or thiadiazolyl, and each of these heterocyclic rings is connected through a carbon atom and
  • R j 4 is hydrogen or R7; or when R8 and R14 are as NR8R14 they may together with the nitrogen form a 5 to 7 membered ring comprised of carbon or carbon and one or more additional heteroatoms selected from O, N, or S; R 15 is C(O)Ri4, C(O)NR4Rl4, S(O)2R7, or S(O)2.NR4Rl4; or the pharmaceutically acceptable salts thereof.
  • This invention also relates to the pharmaceutical compositions comprising a compound of Formula (I) and a pharmaceutically acceptable carrier or diluent
  • the invention also relates to a method of mediation or inhibition of the enzymatic activity (or catalytic activity) of PDE IV in mammals, including humans, which comprises administering to a mammal in need thereof an effective amount of a compound of Formula (I) as shown below.
  • the invention further provides a method for the treatment of allergic and inflammatory disease which comprises administering to a mammal, including humans, in need thereof, an effective amount of a compound of Formula (I).
  • the invention also provides a method for the treatment of asthma which comprises administering to a mammal, including humans, in need thereof, an effective amount of a compound of Formula (I).
  • This invention also relates to a method of inhibiting TNF production in a mammal, including humans, which method comprises administering to a mammal in need of such treatment, an effective TNF inhibiting amount of a compound of Formula (I).
  • This method may be used for the prophylactic treatment or prevention of certain TNF mediated disease states amenable thereto.
  • This invention also relates to a method of treating a human afflicted with a human immunodeficiency virus (HTV), which comprises administering to such human an effective TNF inhibiting amount of a compound of Formula (I).
  • HTV human immunodeficiency virus
  • Compounds of Formula (I) are also useful in the treatment of additional viral infections, where such viruses are sensitive to upregula ⁇ on by TNF or will elicit TNF production in vivo.
  • compounds of Formula (I) are also useful in treating yeast and fungal infections, where such yeast and fungi are sensitive to upregulation by TNF or will elicit TNF production in vivo.
  • This invention also relates to a method of mediating or inhibiting the enzymatic activity (or catalytic activity) of PDE IV in a mammal in need thereof and to inhibiting the production of TNF in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound of Formula (I).
  • Phosphodiesterase IV inhibitors are useful in the treatment of a variety of allergic and inflammatory diseases including: asthma, chronic bronchitis, atopic dermatitis, urticaria, allergic rhinitis, allergic conjunctivitis, vernal conjunctivitis, eosinophilic granuloma, psoriasis, rheumatoid arthritis, septic shock, ulcerative colitis, Crohn's disease, reperfusion injury of the myocardium and brain, chronic glomerulonephritis, endotoxic shock and adult respiratory distress syndrome.
  • PDE IV inhibitors are useful in the treatment of diabetes insipidus and central nervous system disorders such as depression and multi-infarct dementia.
  • viruses contemplated for treatment herein are those that produce TNF as a result of infection, or those which are sensitive to inhibition, such as by decreased replication, directly or indirectly, by the TNF inhibitors of Formula (I).
  • viruses include, but are not limited to HIV-1, HIV-2 and HIV-3, cytomegalovirus (CMV), influenza, adenovirus and the Herpes group of viruses, such as, but not limited to, Herpes zoster and Herpes simplex.
  • This invention more specifically relates to a method of treating a mammal, afflicted with a human immunodeficiency virus (HTV), which comprises administering to such mammal an effective TNF inhibiting amount of a compound of Formula (I).
  • HTV human immunodeficiency virus
  • TNF mediated diseases for treatment, therapeutically or prophylactically, in animals include disease states such as those noted above, but in particular viral infections.
  • viruses include, but are not limited to feline immunodeficiency virus (FTV) or other retroviral infection such as equine infectious anemia virus, caprine arthritis virus, visna virus, maedi virus and other lentiviruses.
  • FTV feline immunodeficiency virus
  • retroviral infection such as equine infectious anemia virus, caprine arthritis virus, visna virus, maedi virus and other lentiviruses.
  • the compounds of this invention are also useful in treating yeast and fungal infections, where such yeast and fungi are sensitive to upregulation by TNF or will elicit TNF production in vivo.
  • a preferred disease state for treatment is fungal meningitis.
  • the compounds of Formula (I) may be administered in conjunction with other drugs of choice for systemic yeast and fungal infections.
  • Drugs of choice for fungal infections include but are not limited to the class of compounds called the polymixins, such as Polymycin B, the class of compounds called the imidazoles, such as clotrimazole, econazole, miconazole, and ketoconazole; the class of compounds called the triazoles, such as fluconazole, and itranazole, and the class of compound called the Amphotericins, in particular Amphotericin B and liposomal Amphotericin B.
  • polymixins such as Polymycin B
  • imidazoles such as clotrimazole, econazole, miconazole, and ketoconazole
  • triazoles such as fluconazole, and itranazole
  • Amphotericins in particular Amphotericin B and liposomal Amphotericin B.
  • the compounds of Formula (I) may also be used for inhibiting and/or reducing the toxicity of an anti-fungal, anti-bacterial or anti-viral agent by administering an effective amount of a compound of Formula (I) to a mammal in need of such treatment
  • a compound of Formula (I) is administered for inhibiting or reducing the toxicity of the Amphotericin class of compounds, in particular Amphotericin B.
  • C ⁇ alkyl C1.4 alkyl
  • C ⁇ _6 alkyl or “alkyl” groups as used herein is meant to include both straight or branched chain radicals of 1 to 10, unless the chain length is limited thereto, including, but not limited to methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, and the like.
  • Alkenyl means both straight or branched chain radicals of 1 to 6 carbon lengths, unless the chain length is limited thereto, including but not limited to vinyl, 1- propenyl, 2-propenyl, 2-propynyl, or 3-methyl-2-propenyl.
  • cycloalkyl or "cycloalkyl alkyl” means groups of 3-7 carbon atoms, such as cyclopropyl, cyclopropylmethyl, cyclopentyl, or cyclohexyl.
  • Aryl or “aralkyl”, unless specified otherwise, means an aromatic ring or ring system of 6-10 carbon atoms, such as phenyl, benzyl, phenethyl, or naphthyl. Preferably the aryl is monocyclic, i.e, phenyl.
  • the alkyl chain is meant to include both straight or branched chain radicals of 1 to 4 carbon atoms.
  • Heteroaryl means an aromatic ring system containing one or more heteroatoms, such as imidazolyl, triazolyl, oxazolyl, pyridyl, pyrimidyl, pyrazolyl, pyrrolyl, furanyl, or thienyl.
  • Halo means all halogens, i.e., chloro, fluoro, bromo, or iodo.
  • “Inhibiting the production of IL-1” or “inhibiting the production of TNF” means: a) a decrease of excessive in vivo EL-1 or TNF levels, respectively, in a human to normal levels or below normal levels by inhibition of the in vivo release of IL-1 by all cells, including but not limited to monocytes or macrophages; b) a down regulation, at the translational or transcriptional level, of excessive in vivo IL-1 or TNF levels, respectively, in a human to normal levels or below normal levels; or c) a down regulation, by inhibition of the direct synthesis of IL-1 or TNF levels as a postranslational event
  • TNF mediated disease or disease states means any and all disease states in which TNF plays a role, either by production of TNF itself, or by TNF causing another cytokine to be released, such as but not limited to IL-1 or DL-6.
  • TNF- ⁇ also known as lymphotoxin
  • TNF- ⁇ also known as cachectin
  • both TNF- ⁇ and TNF- ⁇ arc inhibited by the compounds of the present invention and thus are herein referred to collectively as 'TNF” unless specifically delineated otherwise.
  • TNF- ⁇ is inhibited.
  • Cytokine means any secreted polypeptide that affects the functions of cells, and is a molecule which modulates interactions between cells in immune, inflammatory, or hematopoietic responses.
  • a cytokine includes, but is not limited to, monokines and lymphokines regardless of which cells produce them.
  • the cytokine inhibited by the present invention for use in the treatment of a HTV-infected human must be a cytokine which is implicated in (a) the initiation and/or maintenance of T cell activation and/or activated T cell-mediated HTV gene expression and/or replication, and/or (b) any cytokine-mediated disease associated problem such as cachexia or muscle degeneration.
  • this cytokine is TNF- ⁇ .
  • All of the compounds of Formula (I) are useful in the method of inhibiting the production of TNF, preferably by macrophages, monocytes or macrophages and monocytes, in a mammal, including humans, in need thereof. All of the compounds of Formula (I) are useful in the method of inhibiting or mediating the enzymatic or catalytic activity of PDE TV and in treatment of disease states mediated thereby.
  • Preferred compounds are as follows:
  • R ⁇ may be a cyclopentyl group and a CF3 group within the same molecule of a given embodiment of Formula (I).
  • each and every one of the other groups may be independently selected, or may be the same, in any given embodiment of this invention.
  • the halogens are preferably fluorine and chlorine, more preferably a Ci-4 alkyl substituted by 1 or more fluorines.
  • the preferred halo-substituted alkyl chain length is one or two carbons, and most preferred are the moieties -CF3, -CH2F, -CHF2, -CF2CHF2, -CH2CF3, and - CH2CHF2.
  • Preferred Ri substitutents are CH2-cyclopropyl, CH2-C5-6 cycloalkyl, C4-6 cycloalkyl with or without an OH group, C7-I l polycycloalkyl, (3- or 4- cyclopentenyl), phenyl, tetrahydrofuran-3-yl, benzyl or Ci-2 alkyl optionally substituted by 1 or more fluorines, -(CH2)l-3C(O)O(CH2)0-2CH3, -(CH2)1-3O(CH2)0-2CH3, and -(CH2)2-4OH.
  • R ⁇ term contains the moiety (CR4R5)
  • the R4 and R5 terms are independently hydrogen or alkyl. This allows for branching of the individual methylene units as (CR4R5) n or (CR4R5) m ; each repeating methylene unit is independent of the other, e.g., (CR4R5) n wherein n is 2 can be -CH2CH(-CH3)-, for instance.
  • the individual hydrogen atoms of the repeating methylene unit or the branching hydrocarbon can optionally be substituted by fluorine independent of each other to yield, for instance, the preferred Ri substitutions, as noted above.
  • R 1 is a C7.11 polycycloalkyl
  • examples are bicyclo[2.2.1 ]-heptyl, bicyclo[2.2.2]octyl, bicyclo[3.2.1]octyl, tricyclo[5.2.1.0 2 *'->]decyl, etc. additional examples of which are described in Saccamano et al, WO 87/06576, published 5 November 1987.
  • W is preferably alkyl, alkenyl or alkynyl of 3 to 5 carbon atoms, and where it is alkenyl or alkynyl, that one or two double or triple bonds be present.
  • Z is preferably CR R8OR14, CR8 8 R15, CR8R8SR14, CR8R8SR15, CR8R8S(O) m 'R7.
  • X is preferably H, OH, OCH3, CN, C(O)R8, C(O)OH, C(O)OCH3, C(O)NH2, CON(CH3)2, NH2, or N(CH3)2.
  • the most preferred X4 groups are H, OH, CN, C(O)OH, C(O)NH2 or NH2.
  • Preferred X groups are those wherein X is YR2 and Y is oxygen.
  • the preferred X2 group is oxygen.
  • the preferred X3 is hydrogen.
  • Preferred R2 groups, where applicable, are Ci-2 alkyl unsubstituted or substituted by 1 or more halogens.
  • the halogen atoms are preferably fluorine and chlorine, more preferably fluorine.
  • More preferred R2 groups are those wherein R2 is methyl, or the fluoro- substituted alkyls, specifically a Ci-2 alkyl, such as a -CF3, -CHF2, or -CH2CHF2 moiety. Most preferred are the -CHF2 and -CH3 moieties.
  • R7 moieties include optionally substituted -(CH2)l-2(cyc 1 op r opyl), -(CH2)0-2(cyclobutyl), -(CH2)0-2(cyclopentyl) with or without an OH group, -(CH2)0-2(cyclohexyl), -(CH2)0-2(2-, 3- or 4-pyridyl), -(CH2) l-2(2-imidazolyl),
  • Preferred rings when Rio and Ri 1 in the moiety -NRioRl 1 together with the nitrogen to which they are attached form a 5 to 7 membered ring containing at least one additional heteroatom selected from O, N or S include, but are not limited to 1- imidazolyl, 2-(R8)-l-imidazolyl, 1-pyrazolyl, 3-(R8H-pyrazolyl, 1-triazolyl, 2- triazolyl, 5-(R8)-l-triazolyl, 5-(R8)-2-triazolyl, 5-(R8)-l-tetrazolyl, 5-(R8)-2-tetrazolyl, 1-tetrazolyl, 2-tetrazloyl, morpholinyl, piperazinyl, 4-(Rs)-l- piperazinyl, or pyrrolyl ring.
  • Preferred rings when Rio and R 14 in the moiety -NR10R14 together with the nitrogen to which they are attached form a 5 to 7 membered ring containing at least one additional heteroatom selected from O, N or S include, but are not limited to 1- imidazolyl, 1 -pyrazolyl, 1-triazolyl, 2-triazolyl, 1-tetrazolyl, 2-tetrazolyl. morpholinyl, piperazinyl, and pyrrolyl. The respective rings may be additionally substituted, where applicable, on an available nitrogen or carbon by the moiety R7 as described herein for Formula (I).
  • Illustrations of such carbon substitutions includes, but are not limited to, 2-(R7)-l-imidazolyl, 4-(R7)-l-imidazolyl, 5-(R7)-l-imidazolyl, 3-(R7)-l -pyrazolyl, 4-(R7)-l -pyrazolyl, 5-(R7)-l -pyrazolyl, 4-(R7)-2-triazolyl, 5-(R7)-2-triazolyl, 4-(R7)-l-triazolyl, 5-(R7)-l-triazolyl, 5-(R7)-l-tetrazolyl, and 5-(R7)-2-tetrazolyl.
  • R7 Applicable nitrogen substitution by R7 includes, but is not limited to, l-(R7)-2-tetrazolyl, 2-(R7)-l-tetrazolyl, 4-(R7)-l -piperazinyl. Where applicable, the ring can be substituted one or more times by R7.
  • Preferred groups for NR10R14 which contain a heterocyclic ring are 5-(Ri4)- 1-tetrazolyl, 2-(Ri4)-l-imidazolyl, 5-(Ri4)-2-tet ⁇ azolyl, or 4-(R 14 )- 1 -piperazinyl.
  • Preferred rings for R13 include (2-, 4- or 5-imidazolyl), (3-, 4- or 5-pyrazolyl), (4- or 5-triazolyl[ 1,2,3]), (3- or 5-triazolyl[ 1,2,4]), (5-tetrazolyl), (2-, 4- or 5-oxazolyl), (3-, 4- or 5-isoxazolyl), (3- or 5-oxadiazolyl[ 1,2,4]), (2-oxadiazolyl[l,3,4]), (2-thiadiazolyl[ 1,3,4]), (2-, 4-, or 5-thiazolyl), (2-, 4-, or 5-oxazolidinyl), (2-, 4-, or 5-thiazolidinyl), or (2-, 4-, or 5-imidazolidinyl).
  • the heterocyclic ring itself may be optionally substituted by R8 either on an available nitrogen or carbon atom, such as l-(R8)-2-imidazolyl, l-(R8)-4-imidazolyl, l-(R8)-5-imidazolyl, l-(R8)-3-pyrazolyl, l-(R8)-4-pyrazolyl, l-(R8)-5-pyrazolyl, l-(R8)-4-triazolyl, or l-(R8)-5-triazolyl.
  • the ring may be substituted one or more times by Rg.
  • Rj is -CH2- cyclopropyl, -CH2-C5-6 cycloalkyl, -C4-6 cycloalkyl unsubstituted or substituted with an hydroxyl group, tetrahydrofuran-3-yl, (3- or 4-cyclopentenyl), benzyl or -Ci-2 alkyl optionally substituted by 1 or more fluorines, and -(CH2)2-4 OH; R2 is methyl or fluoro-substituted alkyl, and W is alkynyl of 2 to 4 carbon atoms.
  • Ri is -CH2-cyclopropyl, cyclopentyl, 3-hydroxycyclopentyl, methyl or CF2H
  • X is YR2; Y is oxygen; X2 is oxygen; X3 is hydrogen; X4 is hydrogen, R2 is CF2H or methyl, W is 1,3-butadiynyl, and in Z the R8 group is H and the R14 group of Z is R4.
  • Exemplified compound is:
  • salts of the instant compounds where they can be prepared, are also intended to be covered by this invention. These salts will be ones which are acceptable in their application to a pharmaceutical use. By that it is meant that the salt will retain the biological activity of the parent compound and the salt will not have untoward or deleterious effects in its application and use in treating diseases.
  • compositions are prepared in a standard manner.
  • the parent compound, dissolved in a suitable solvent is treated with an excess of an organic or inorganic acid, in the case of acid addition salts of a base, or an excess of organic or inorganic base where the molecule contains a COOH for example.
  • compositions of the present invention comprise a pharmaceutical carrier or diluent and some amount of a compound of the formula (I).
  • the compound may be present in an amount to effect a physiological response, or it may be present in a lesser amount such that the user will need to take two or more units of the composition to effect the treatment intended.
  • These compositions may be made up as a solid, liquid or in a gaseous form. Or one of these three forms may be transformed to another at the time of being administered such as when a solid is delivered by aerosol means, or when a liquid is delivered as a spray or aerosol.
  • the nature of the composition and the pharmaceutical carrier or diluent will, of course, depend upon the intended route of administration, for example parenterally, topically, orally or by inhalation.
  • the pharmaceutical composition will be in the form of a cream, ointment, liniment, lotion, pastes, aerosols, and drops suitable for administration to the skin, eye, ear, or nose.
  • the pharmaceutical composition will be in the form of a sterile injectable liquid such as an ampule or an aqueous or non-aqueous liquid suspension.
  • the pharmaceutical composition will be in the form of a tablet, capsule, powder, pellet, atroche, lozenge, syrup, liquid, or emulsion.
  • examples of appropriate pharmaceutical carriers or diluents include: for aqueous systems, water, for non-aqueous systems, ethanol, glycerin, propylene glycol, corn oil, cottonseed oil, peanut oil, sesame oil, liquid parafins and mixtures thereof with water, for solid systems, lactose, kaolin and mannitol; and for aerosol systems, dichlorodifluoromethane, chlorotrifluoroethane and compressed carbon dioxide.
  • the instant compositions may include other ingredients such as stabilizers, antioxidants, preservatives, lubricants, suspending agents, viscosity modifiers and the like, provided that the additional ingredients do not have a detrimental effect on the therapeutic action of the instant compositions.
  • the pharmaceutical preparations thus described are made following the conventional techniques of the pharmaceutical chemist as appropriate to the desired end product.
  • the amount of carrier or diluent will vary but preferably will be the major proportion of a suspension or solution of the active ingredient.
  • the diluent is a solid it may be present in lesser, equal or greater amounts than the solid active ingredient
  • Topical formulations will contain between about 0.01 to 5.0% by weight of the active ingredient and will be applied as required as a preventative or curative agent to the affected area.
  • the dosage of the composition is selected from the range of from 50 mg to 1000 mg of active ingredient for each administration.
  • equal doses will be administered 1 to 5 times daily with the daily dosage regimen being selected from about 50 mg to about 5000 mg.
  • Compounds of Formula (I), wherein W is a 1,3-butadiyne and wherein A and B represent Z as defined in relation to Formula (I) or a group convertible to Z and wherein X4 represents X4 as defined in relation to Formula (I) or a group convertible to X4, may be prepared by the processes disclosed herein which comprise, for example, coupling of a molecule of the Formula 1 -Scheme 1 with a molecule of the Formula 2- Scheme 1 using an appropriate metal salt, such as cupric acetate, in a suitable solvent such as DMF or pyridine, or a combination, such as pyridine/methanol/water, as in the method of Eglington and Galbraith (J. Chem. Soc., 1959, 889), to provide a compound of the Formula 3- Scheme 1.
  • an appropriate metal salt such as cupric acetate
  • a suitable solvent such as DMF or pyridine
  • a combination such as pyridine/methanol/water
  • Reduction of a compound of the Formula (I), wherein W is a 1,3-butadiyne and wherein Z represents Z as defined in relation to Formula (I) or a group convertible to Z and wherein X4 represents X4 as defined in relation to Formula (I) or a group convertible to X4, to a compound of the Formula (I) wherein W is a fully saturated hydrocarbon chain (i.e., n-butyl) may be accomplished using, e.g., palladium metal according to the method of Tedeschi (J. Org.
  • Reduction of a compound of the Formula (I), wherein W is a 1,3-butadiyne and wherein Z represents Z as defined in relation to Formula (I) or a group convertible to Z and wherein X4 represents X4 as defined in relation to Formula (I) or a group convertible to X4, to provide a compound of the Formula 0) wherein W is a 1,3-butadiene may be accomplished using, e.g., the hydroboration-protonolysis procedure of Zweifel and Polston (J. Am. Chem. Soc., 1970, 92, 4068), or, e.g., the hydroalumination-protonolysis procedure of Zweifel et al. (Synthesis, 1977, 52).
  • compounds of the Formula (1) wherein W, X4 and Z represent W, X4 and Z as defined in relation to Formula (I) or a group convertible to W, X4 or Z, may be prepared from the corresponding ketones as, e.g., compound 1- Scheme 2.
  • synthetic procedures described in United States patent applications 08/131054 and PCT application PCT/US94/10816 syntheses of such ketone starting materials are described in co-pending U.S. applications 08/130215 filed 01 October 1993 and PCT/US94/10815 filed 23 September 1994 or co-pending USSN 08/130213 and PCT application PCT/US94/10767 filed on 01 October 1993 and 23 September 1994 respectively.
  • the Zand X4 groups may require protection during the coupling and or reductive steps described herein, followed by deprotection, to provide the Formula (I) compound, as in processes described in co-pending U.S. application filed on even date herewith and identified as P50301; such protective groups are well known to those skilled in the art (See: Greene, T. and Wuts, P.G.M., Protecting Groups in Organic Synthesis, 2nd Ed., John Wiley and Sons, New York, 1991.)
  • Example 1 Preparation of 1.4-to-f rc-3-(3-cyclopentyloxy-4-methoxyphenyl -l- hvdroxvmethvlcvclohexanl-3-vnhuta-l .3-divne
  • a suspension of ⁇ ,4-bis- ⁇ [methyl c-3-(3-cyclopentyloxy-4-methoxyphenyl)-r- 1-cyclohexane carboxylate]-3-yl ⁇ buta-l,3-diyne (0.35 g, 0.52 mmol, prepared as described in co-pending U.S.
  • Example 2 Preparation of 1.4-fei.y-(rr-3-(3-cvclopentvloxv-4-methoxvphenvlVr-l- aminomcthvlcvclohcxan.- -vl lhuta-1.3-divne
  • a solution of l,4-t is- ⁇ [c-3-(3-cyclopentyloxy-4-methoxyphenyl)-r-l- hydroxymethylcyclohexan]-3-yl)buta-l,3-diyne (0.11 g, 0.16 mmol) in tetrahydrofuran (2 mL) under an argon atmosphere is treated with triphenylphosphine (0.08 g, 0.32 mmol) , phthalimide (0.04 g, 0.32 mmol) and then diethylazodicarboxylate (0.06 mL, 0.32 mmol) is added dropwise.
  • the reaction flask is covered with foil and the mixture is stirred at room temperature for 30 h.
  • the solvent is evaporated and the residue is purified by flash column chromatography, to provide the product phthalimide, which is dissolved in ethanol (0.5 mL) under an argon atmosphere and is stirred with hydrazine hydrate (0.16 mL, 0.3 mmol) for 3 days.
  • the precipitate is removed by filtration, the filtrate is applied to a silica column and the product is eluted.
  • the phosphodiesterase inhibitory activity and selectivity of the compounds of Formula (I) can be determined using a battery of five distinct PDE isozymes.
  • the tissues used as sources of the different isozymes are as follows: 1) PDE lb, porcine aorta; 2) PDE lc, guinea-pig heart; 3) PDE m, guinea-pig heart; 4) PDE IV, human monocyte; and 5) PDE V (also called "la”), canine trachealis.
  • PDEs la, lb, lc and III are partially purified using standard chromatographic techniques [Torphy and Cieslinski, Mol. Pharmacol., 37:206-214, 1990].
  • PDE IV is purified to kinetic homogeneity by the sequential use of anion-exchange followed by heparin-Sepharose chromatography [Torphy et al, J. Biol. Chem., 267:1798-1804, 1992].
  • Phosphodiesterase activity is assayed as described in the protocol of Torphy and Cieslinski, Mol. Pharmacol., 37:206-214, 1990. Positive ICso's in the nanomolar to ⁇ M range for compounds of the workings examples described herein for Formula (I) have been demonstrated.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

This invention relates to certain 1,3,3-(trisubstituted)cyclohexane dimers and related compounds which are useful in treating allergic and inflammatory diseases and for inhibiting the production of Tumor Necrosis Factor (TNF).

Description

l 3* -(Trisubstituted)cyclohexane Dimers and Related Compounds Field of Invention
The present invention relates to novel l,3,3-(trisubstituted)cyclohexane dimers and related compounds, pharmaceutical compositions containing these compounds, and their use in treating allergic and inflammatory diseases and for inhibiting the production of Tumor Necrosis Factor (TNF). Background of the Invention
Bronchial asthma is a complex, multifactorial disease characterized by reversible narrowing of the airway and hyperreactivity of the respiratory tract to external stimuli.
Identification of novel therapeutic agents for asthma is made difficult by the fact that multiple mediators are responsible for the development of the disease. Thus, it seems unlikely that eliminating the effects of a single mediator will have a substantial effect on all three components of chronic asthma. An alternative to the "mediator approach" is to regulate the activity of the cells responsible for the pathophysiology of the disease.
One such way is by elevating levels of c AMP (adenosine cyclic 3',5'- monophosphate). Cyclic AMP has been shown to be a second messenger mediating the biologic responses to a wide range of hormones, neurotransmitters and drugs; [Krebs Endocrinology Proceedings of the 4th International Congress Excerpta Medica, 17-29, 1973]. When the appropriate agonist binds to specific cell surface receptors, adenylate cyclase is activated, which converts Mg+*^-ATP to cAMP at an accelerated rate.
Cyclic AMP modulates the activity of most, if not all, of the cells that contribute to the pathophysiology of extrinsic (allergic) asthma. As such, an elevation of c AMP would produce beneficial effects including: 1) airway smooth muscle relaxation, 2) inhibition of mast cell mediator release, 3) suppression of neutrophil degranulation, 4) inhibition of basophil degranulation, and 5) inhibition of monocytc and macrophage activation. Hence, compounds that activate adenylate cyclase or inhibit phosphodiesterase should be effective in suppressing the inappropriate activation of airway smooth muscle and a wide variety of inflammatory cells. The principal cellular mechanism for the inactivation of cAMP is hydrolysis of the 3'- phosphodiester bond by one or more of a family of isozymes referred to as cyclic nucleotide phosphodiesterases (PDEs).
It has now been shown that a distinct cyclic nucleotide phosphodiesterase (PDE) isozyme, PDE IV, is responsible for cAMP breakdown in airway smooth muscle and inflammatory cells. [Torphy, "Phosphodiesterase Isozymes: Potential Targets for Novel Anti-asthmatic Agents" in New Drugs for Asthma, Barnes, ed. IBC Technical Services Ltd., 1989]. Research indicates that inhibition of this enzyme not only produces airway smooth muscle relaxation, but also suppresses degranulation of mast cells, basophils and neutrophils along with inhibiting the activation of monocytes and neutrophils. Moreover, the beneficial effects of PDE IV inhibitors are markedly potentiated when adenylate cyclase activity of target cells is elevated by appropriate hormones or autocoids, as would be the case in vivo. Thus PDE IV inhibitors would be effective in the asthmatic lung, where levels of prostaglandin E2 and prostacyclin (activators of adenylate cyclase) are elevated. Such compounds would offer a unique approach toward the pharmacotherapy of bronchial asthma and possess significant therapeutic advantages over agents currently on the market.
The compounds of this invention also inhibit the production of Tumor Necrosis Factor (TNF), a serum glycoprotein. Excessive or unregulated TNF production has been implicated in mediating or exacerbating a number of diseases including rheumatoid arthritis, rheumatoid spondylitis, ostectarthriύs, gouty arthritis and other arthritic conditions; sepsis, septic shock, endotoxic shock, gram negative sepsis, toxic shock syndrome, adult respiratory distress syndrome, cerebral malaria, chronic pulmonary inflammatory disease, silicosis, pulmonary sarcoidosis, bone resorption diseases, reperfusion injury, graft vs. host reaction, allograft rejections, fever and myalgias due to infection, such as influenza, cachexia secondary to infection or malignancy, cachexia secondary to human acquired immune deficiency syndrome
(AIDS), AIDS, ARC (AIDS related complex), keloid formation, scar tissue formation, Crohn's disease, ulcerative colitis, or pyresis, in addition to a number of autoimmune diseases, such as multiple sclerosis, autoimmune diabetes and systemic lupus erythematosis. AIDS results from the infection of T lymphocytes with Human
Immunodeficiency Virus (HTV). At least three types or strains of HTV have been identified, i.e., HIV-1, HIV-2 and HIV-3. As a consequence of HIV infection, T-cell- mediated immunity is impaired and infected individuals manifest severe opportunistic infections and/or unusual neoplasms. HTV entry into the T lymphocyte requires T lymphocyte activation. Viruses such as HTV- 1 or HTV-2 infect T lymphocytes after T cell activation and such virus protein expression and/or replication is mediated or maintained by such T cell activation. Once an activated T lymphocyte is infected with HIV, the T lymphocyte must continue to be maintained in an activated state to permit HIV gene expression and/or HTV replication. Cytokines, specifically TNF, are implicated in activated T-cell-mediated HTV protein expression and/or virus replication by playing a role in maintaining T lymphocyte activation. Therefore, interference with cytokine activity such as by inhibition of cytokine production, notably TNF, in an HTV-infected individual aids in limiting the maintenance of T cell activation, thereby reducing the progression of HTV infectivity to previously uninfected cells which results in a slowing or elimination of the progression of immune dysfunction caused by HTV infection. Monocytes, macrophages, and related cells, such as kupffer and glial cells, have also been implicated in maintenance of the HTV infection. These cells, like T cells, are targets for viral replication and the level of viral replication is dependent upon the activation state of the cells. [See Rosenberg et al, The Immunopathogenesis of HIV Infection, Advances in Immunology, Vol. 57, 1989]. Monokines, such as TNF, have been shown to activate HTV replication in monocytes and or macrophages [See Poli et al., Proc. Natl. Acad. Sci., 87:782-784, 1990], therefore, inhibition of monokine production or activity aids in limiting HTV progression as stated above for T cells.
TNF has also been implicated in various roles with other viral infections, such as the cytomegalovirus (CMV), influenza virus, adenovirus, and the herpes virus for similar reasons as those noted.
TNF is also associated with yeast and fungal infections. Specifically Candida albicans has been shown to induce TNF production in vitro in human monocytes and natural killer cells. [See Riipi et al, Infection and Immunity, 58(9):2750-54, 1990; and Jafari et al, Journal of Infectious Diseases, 164:389-95, 1991. See also Wasan et al, Antimicrobial Agents and Chemotherapy, 35,(10):2046-48, 1991; and Luke et al, Journal of Infectious Diseases, 162:211-214,1990]. The ability to control the adverse effects of TNF is furthered by the use of the compounds which inhibit TNF in mammals who are in need of such use. There remains a need for compounds which are useful in treating TNF-mediated disease states which are exacerbated or caused by the excessive and/or unregulated production of TNF. Summary of the Invention
The compounds of this invention are represented by Formula (I):
Figure imgf000005_0001
(I) wherein:
Rl is independently selected from -(CR4R5)nC(O)O(CR4R5)mR6,
-(CR4R5)nC(O)NR4(CR4R5)mR6, -(CR4R5)nO(CR4R5)mR6, or -(CR4R5)rR wherein the alkyl moieties is unsubstituted or substituted with one or more fluorines; m is 0 to 2; n is 1 to 4; r is 0 to 6;
R4 and R5 are independently selected from hydrogen or Ci-2 alkyl; R6 is independently selected from hydrogen, methyl, hydroxyl, aryl, halo substituted aryl, aryloxyCi-3 alkyl, halo substituted aryloxyCl-3 alkyl, indanyl, indenyl, C7-11 polycycloalkyl, tetrahydrofuranyl, furanyl, tetrahydropyranyl, pyranyl, tetrahydrothienyl, thienyl, tetrahydrothiopyranyl, thiopyranyl, C3-6 cycloalkyl, or a C4- 6 cycloalkyl containing one or two unsaturated bonds, wherein the cycloalkyl or heterocyclic moiety is unsubstituted or substituted by 1 to 3 methyl groups, one ethyl group, or an hydroxyl group; provided that: a) when R6 is hydroxyl, then m is 2; or b) when R6 is hydroxyl, then r is 2 to 6; or c) when R6 is 2-tetrahydropyranyl, 2-tetrahydrothiopyranyl, 2-tetrahydrofuranyl, or 2-tetrahydrothienyl, then m is 1 or 2; or d) when R6 is 2-tetrahydropyranyl, 2-tetrahydrothiopyranyl, 2-tetrahydrofuranyl, or 2-tetrahydrothienyl, then r is 1 to 6; e) when n is 1 and m is 0, then R6 is other than H in
-(CR4R5)nO(CR4R5)mR6; X is independently selected from YR2, fluorine, NR4R5, or formyl amine;
Y is independently selected from O or S(O)m'; m' is O, l, or 2;
X2 is independently selected from O or NR8;
X3 is independently selected from hydrogen or X; R2 is independently selected from the group consisting of -CH3 and -CH2CH3 optionally substituted by 1 or more fluorines; s is 0 to 4; W is alkyl of 2 to 6 carbons, alkenyl of 2 to 6 carbon atoms or alkynyl of 2 to 6 carbon atoms; Z is independently CR8R8OR14, CR8 8OR15, CRδ δSR , CR8R8SR15,
CRδ δS O R?, CR8R8NR10R14, CR8R8NRlθS(O)2NRlθRl4, CR8R8NRlθS(O)2R7, CR8R8NRlθC(Y')Rl4, CR8R8NRlθC(O)OR7, CR8R8NRlθC(Y') RlθRl4, CR8R8NRlθC(NCN)NRιoRl4, CR8R8NRlθC(CR4Nθ2)NRιθRl4, CR8R8NRlθC(NCN)SR9, CR8R8 R10C(CR4NO2)SR9, CR8RδC(O)ORi4, CR8R8C(Y')NRlθRl4, CR8R8C(NRiθ)NRlθRl4, CRδRδCN, CR8R8(tetrazolyl), CR8R8(imidazolyl), CR8R8("nidazolidinyl), CR8R8(pyrazolyl), CR8R8(Λiazolyl), CR8R8(thiazolidinyl), CR8R8(oxazolyl), CR8R8(oxazolidinyl), CRδRβOriazolyl), CR8R8(i∞xazolyl), CR8R8(oxadiazolyl), CR8R8 (thiadiazolyl), CR8R8(πwrpholinyl), CRsRβCpipeπdinyl), CR8R8(pipcrazinyl), CR8R8(p rrolyl), CR8R8C(NOR8)Rl4, CR8RδC(NORi4 R8. CR8R8NRlθC(NRlO)SR9, CR8R8NRlθC(NRlO)NRi()Ri4, CR8R8NRlθC(O)C(O)NRιoRl4, or CR8R8NRlθC(O)C(O)ORi4; X5 is H, R9, OR8, CN, C(O)R8, C(O)OR8, C(O)NR8R8, or NR8R8; X4 is independently H, R9, OR8, CN, C(O)R8, C(O)OR8, C(O)NRsR8, or
NR8R8;
Y' is independently selected from O or S;
R7 is -(CR4R5)ςRi2 or Cj.β alkyl wherein the Rl2 or Cj.g alkyl group is unsubstituted or substituted one or more times by methyl or ethyl unsubstituted or substituted by 1-3 fluorines, -F, -Br, -Cl, -NO2, -NRioRl 1* -C(0)R8, -CO2R8, -O(CH2)qR8, -CN, -C(O)NRιoRl l, -O(CH2)qC(O)NRlθRl l, -O(CH2)qC(O)R9, -NRιoC(O)NRιoRl l, -NRlθC(O)Rn, -NRιoC(O)OR9, -NRιoC(O)Ri3, -C(NRiθ)NRlθRl l, -C(NCN)NRιoRl l, -C(NCN)SR9, -NRιoC(NCN)SR9 , -NRloC(NCN)NRlθRl l, -NRιoS(O)2R9, -S(O)m'R9, -NRιoC(O)C(O)NRiθRl l, - NRιoC(O)C(O)Rιo, or R13; q is O, l, or 2;
Rl2 is independently selected from R13, C3.7 cycloalkyl, (2-, 3- or 4-pyridyl), pyrimidyl, pyrazolyl, (1- or 2-imidazolyl), pyirolyl, piperazinyl, piperidinyl, mo holinyl, furanyl, (2- or 3-thienyl), quinolinyl, naphthyl, or phenyl; R is independently selected from hydrogen or R9;
R9 is independently selected from C1.4 alkyl optionally substituted by one to three fluorines;
RjO is independently selected from OR8 or Ri 1;
Rχi is independently selected from hydrogen, or C 1.4 alkyl optionally substituted by one to three fluorines; or when R10 and Ri l are as NRioRl 1 they may together with the nitrogen form a 5 to 7 membered ring comprised of carbon or carbon and at least one additional heteroatom selected from O, N, or S;
Rl3 is independently selected from oxazolidinyl, oxazolyl, thiazolyl, pyrazolyl, triazolyl, tetrazolyl, imidazolyl, imidazolidinyl, thiazolidinyl, isoxazolyl, oxadiazolyl, or thiadiazolyl, and each of these heterocyclic rings is connected through a carbon atom and
Rj4 is hydrogen or R7; or when R8 and R14 are as NR8R14 they may together with the nitrogen form a 5 to 7 membered ring comprised of carbon or carbon and one or more additional heteroatoms selected from O, N, or S; R15 is C(O)Ri4, C(O)NR4Rl4, S(O)2R7, or S(O)2.NR4Rl4; or the pharmaceutically acceptable salts thereof.
This invention also relates to the pharmaceutical compositions comprising a compound of Formula (I) and a pharmaceutically acceptable carrier or diluent The invention also relates to a method of mediation or inhibition of the enzymatic activity (or catalytic activity) of PDE IV in mammals, including humans, which comprises administering to a mammal in need thereof an effective amount of a compound of Formula (I) as shown below.
The invention further provides a method for the treatment of allergic and inflammatory disease which comprises administering to a mammal, including humans, in need thereof, an effective amount of a compound of Formula (I).
The invention also provides a method for the treatment of asthma which comprises administering to a mammal, including humans, in need thereof, an effective amount of a compound of Formula (I). This invention also relates to a method of inhibiting TNF production in a mammal, including humans, which method comprises administering to a mammal in need of such treatment, an effective TNF inhibiting amount of a compound of Formula (I). This method may be used for the prophylactic treatment or prevention of certain TNF mediated disease states amenable thereto. This invention also relates to a method of treating a human afflicted with a human immunodeficiency virus (HTV), which comprises administering to such human an effective TNF inhibiting amount of a compound of Formula (I).
Compounds of Formula (I) are also useful in the treatment of additional viral infections, where such viruses are sensitive to upregulaύon by TNF or will elicit TNF production in vivo.
In addition, compounds of Formula (I) are also useful in treating yeast and fungal infections, where such yeast and fungi are sensitive to upregulation by TNF or will elicit TNF production in vivo.
Detailed Description of the Invention This invention also relates to a method of mediating or inhibiting the enzymatic activity (or catalytic activity) of PDE IV in a mammal in need thereof and to inhibiting the production of TNF in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound of Formula (I).
Phosphodiesterase IV inhibitors are useful in the treatment of a variety of allergic and inflammatory diseases including: asthma, chronic bronchitis, atopic dermatitis, urticaria, allergic rhinitis, allergic conjunctivitis, vernal conjunctivitis, eosinophilic granuloma, psoriasis, rheumatoid arthritis, septic shock, ulcerative colitis, Crohn's disease, reperfusion injury of the myocardium and brain, chronic glomerulonephritis, endotoxic shock and adult respiratory distress syndrome. In addition, PDE IV inhibitors are useful in the treatment of diabetes insipidus and central nervous system disorders such as depression and multi-infarct dementia.
The viruses contemplated for treatment herein are those that produce TNF as a result of infection, or those which are sensitive to inhibition, such as by decreased replication, directly or indirectly, by the TNF inhibitors of Formula (I). Such viruses include, but are not limited to HIV-1, HIV-2 and HIV-3, cytomegalovirus (CMV), influenza, adenovirus and the Herpes group of viruses, such as, but not limited to, Herpes zoster and Herpes simplex.
This invention more specifically relates to a method of treating a mammal, afflicted with a human immunodeficiency virus (HTV), which comprises administering to such mammal an effective TNF inhibiting amount of a compound of Formula (I).
The compounds of this invention may also be used in association with the veterinary treatment of animals, other than in humans, in need of inhibition of TNF production. TNF mediated diseases for treatment, therapeutically or prophylactically, in animals include disease states such as those noted above, but in particular viral infections. Examples of such viruses include, but are not limited to feline immunodeficiency virus (FTV) or other retroviral infection such as equine infectious anemia virus, caprine arthritis virus, visna virus, maedi virus and other lentiviruses. The compounds of this invention are also useful in treating yeast and fungal infections, where such yeast and fungi are sensitive to upregulation by TNF or will elicit TNF production in vivo. A preferred disease state for treatment is fungal meningitis. Additionally, the compounds of Formula (I) may be administered in conjunction with other drugs of choice for systemic yeast and fungal infections. Drugs of choice for fungal infections, include but are not limited to the class of compounds called the polymixins, such as Polymycin B, the class of compounds called the imidazoles, such as clotrimazole, econazole, miconazole, and ketoconazole; the class of compounds called the triazoles, such as fluconazole, and itranazole, and the class of compound called the Amphotericins, in particular Amphotericin B and liposomal Amphotericin B. The compounds of Formula (I) may also be used for inhibiting and/or reducing the toxicity of an anti-fungal, anti-bacterial or anti-viral agent by administering an effective amount of a compound of Formula (I) to a mammal in need of such treatment Preferably, a compound of Formula (I) is administered for inhibiting or reducing the toxicity of the Amphotericin class of compounds, in particular Amphotericin B.
The term "C^ alkyl", "C1.4 alkyl", "Cι_6 alkyl" or "alkyl" groups as used herein is meant to include both straight or branched chain radicals of 1 to 10, unless the chain length is limited thereto, including, but not limited to methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, and the like. "Alkenyl" means both straight or branched chain radicals of 1 to 6 carbon lengths, unless the chain length is limited thereto, including but not limited to vinyl, 1- propenyl, 2-propenyl, 2-propynyl, or 3-methyl-2-propenyl.
The term "cycloalkyl" or "cycloalkyl alkyl" means groups of 3-7 carbon atoms, such as cyclopropyl, cyclopropylmethyl, cyclopentyl, or cyclohexyl.
"Aryl" or "aralkyl", unless specified otherwise, means an aromatic ring or ring system of 6-10 carbon atoms, such as phenyl, benzyl, phenethyl, or naphthyl. Preferably the aryl is monocyclic, i.e, phenyl. The alkyl chain is meant to include both straight or branched chain radicals of 1 to 4 carbon atoms. "Heteroaryl" means an aromatic ring system containing one or more heteroatoms, such as imidazolyl, triazolyl, oxazolyl, pyridyl, pyrimidyl, pyrazolyl, pyrrolyl, furanyl, or thienyl.
"Halo" means all halogens, i.e., chloro, fluoro, bromo, or iodo.
"Inhibiting the production of IL-1" or "inhibiting the production of TNF" means: a) a decrease of excessive in vivo EL-1 or TNF levels, respectively, in a human to normal levels or below normal levels by inhibition of the in vivo release of IL-1 by all cells, including but not limited to monocytes or macrophages; b) a down regulation, at the translational or transcriptional level, of excessive in vivo IL-1 or TNF levels, respectively, in a human to normal levels or below normal levels; or c) a down regulation, by inhibition of the direct synthesis of IL-1 or TNF levels as a postranslational event
The phrase 'TNF mediated disease or disease states" means any and all disease states in which TNF plays a role, either by production of TNF itself, or by TNF causing another cytokine to be released, such as but not limited to IL-1 or DL-6. A disease state in which IL-1, for instance is a major component, and whose production or action, is exacerbated or secreted in response to TNF, would therefore be considered a disease state mediated by TNF. As TNF-β (also known as lymphotoxin) has close structural homology with TNF-α (also known as cachectin), and since each induces similar biologic responses and binds to the same cellular receptor, both TNF-α and TNF-β arc inhibited by the compounds of the present invention and thus are herein referred to collectively as 'TNF" unless specifically delineated otherwise. Preferably TNF-α is inhibited. "Cytokine" means any secreted polypeptide that affects the functions of cells, and is a molecule which modulates interactions between cells in immune, inflammatory, or hematopoietic responses. A cytokine includes, but is not limited to, monokines and lymphokines regardless of which cells produce them. The cytokine inhibited by the present invention for use in the treatment of a HTV-infected human must be a cytokine which is implicated in (a) the initiation and/or maintenance of T cell activation and/or activated T cell-mediated HTV gene expression and/or replication, and/or (b) any cytokine-mediated disease associated problem such as cachexia or muscle degeneration. Prefeπably, this cytokine is TNF-α.
All of the compounds of Formula (I) are useful in the method of inhibiting the production of TNF, preferably by macrophages, monocytes or macrophages and monocytes, in a mammal, including humans, in need thereof. All of the compounds of Formula (I) are useful in the method of inhibiting or mediating the enzymatic or catalytic activity of PDE TV and in treatment of disease states mediated thereby. Preferred compounds are as follows:
While the following preferred compounds are more or less described in terms of preferring a symetrical molecule, each substituent described herein above, and below, may be independently varied based on the definitions of each provided herein. For example R\ may be a cyclopentyl group and a CF3 group within the same molecule of a given embodiment of Formula (I). Similarly each and every one of the other groups may be independently selected, or may be the same, in any given embodiment of this invention.
When Ri is an alkyl substituted by 1 or more halogens, the halogens are preferably fluorine and chlorine, more preferably a Ci-4 alkyl substituted by 1 or more fluorines. The preferred halo-substituted alkyl chain length is one or two carbons, and most preferred are the moieties -CF3, -CH2F, -CHF2, -CF2CHF2, -CH2CF3, and - CH2CHF2. Preferred Ri substitutents are CH2-cyclopropyl, CH2-C5-6 cycloalkyl, C4-6 cycloalkyl with or without an OH group, C7-I l polycycloalkyl, (3- or 4- cyclopentenyl), phenyl, tetrahydrofuran-3-yl, benzyl or Ci-2 alkyl optionally substituted by 1 or more fluorines, -(CH2)l-3C(O)O(CH2)0-2CH3, -(CH2)1-3O(CH2)0-2CH3, and -(CH2)2-4OH.
When the R\ term contains the moiety (CR4R5), the R4 and R5 terms are independently hydrogen or alkyl. This allows for branching of the individual methylene units as (CR4R5)n or (CR4R5)m; each repeating methylene unit is independent of the other, e.g., (CR4R5)n wherein n is 2 can be -CH2CH(-CH3)-, for instance. The individual hydrogen atoms of the repeating methylene unit or the branching hydrocarbon can optionally be substituted by fluorine independent of each other to yield, for instance, the preferred Ri substitutions, as noted above. When R 1 is a C7.11 polycycloalkyl, examples are bicyclo[2.2.1 ]-heptyl, bicyclo[2.2.2]octyl, bicyclo[3.2.1]octyl, tricyclo[5.2.1.02*'->]decyl, etc. additional examples of which are described in Saccamano et al, WO 87/06576, published 5 November 1987. W is preferably alkyl, alkenyl or alkynyl of 3 to 5 carbon atoms, and where it is alkenyl or alkynyl, that one or two double or triple bonds be present.
Z is preferably CR R8OR14, CR8 8 R15, CR8R8SR14, CR8R8SR15, CR8R8S(O)m'R7. CR8R8NR10R14, CR8R8NS(O)2NRlθRl4, CR8R8NS(O)2R7, CR8R8NRlθC(O)Ri4, CR8R8 lθC(O)OR7, CR8R8NRlθC(O)NRlθRl4, CR8R8NRl C(NCN)NRιoRl4, CR8R8NRlθC(CR4Nθ2)NRiθRi4, CR8R8NRlθC(NCN)SR9, CR8R8NRlθC(CR4Nθ2)SR , CRδR8C(O)ORi4, CR8R8C(O)NRlθRl4, CR8R8C(NRlO)NRlθRl4, CRδRβCN, CR8R8(oxadiazolyl), CR8R8(thiadiazolyl), CR8R8C(NOR8)Rl4, CR8R8C(NORl4)R8. CR8R8NRlθC(NRιo)SR9, CR8R8 RlθC(NRio)NRlθRl4,
CR8R8NRιoC(O)C(O)NRιoRl4, or CR8R8N lθC(O)C(O)ORi4; most preferred are those compounds wherein the R8 group of Z is H and the R14 group of Z is R4.
X is preferably H, OH, OCH3, CN, C(O)R8, C(O)OH, C(O)OCH3, C(O)NH2, CON(CH3)2, NH2, or N(CH3)2. The most preferred X4 groups are H, OH, CN, C(O)OH, C(O)NH2 or NH2.
Preferred X groups are those wherein X is YR2 and Y is oxygen. The preferred X2 group is oxygen. The preferred X3 is hydrogen. Preferred R2 groups, where applicable, are Ci-2 alkyl unsubstituted or substituted by 1 or more halogens. The halogen atoms are preferably fluorine and chlorine, more preferably fluorine. More preferred R2 groups are those wherein R2 is methyl, or the fluoro- substituted alkyls, specifically a Ci-2 alkyl, such as a -CF3, -CHF2, or -CH2CHF2 moiety. Most preferred are the -CHF2 and -CH3 moieties.
Preferred R7 moieties include optionally substituted -(CH2)l-2(cyc1opropyl), -(CH2)0-2(cyclobutyl), -(CH2)0-2(cyclopentyl) with or without an OH group, -(CH2)0-2(cyclohexyl), -(CH2)0-2(2-, 3- or 4-pyridyl), -(CH2) l-2(2-imidazolyl),
-(CH2)2(4-morpholinyl), -(CH2)2( -piperazinyl), -(CH2)l-2(2-thienyl), -(CH2) 1-2(4- thiazolyl), and -(CH2)0-2phenyl*>
Preferred rings when Rio and Ri 1 in the moiety -NRioRl 1 together with the nitrogen to which they are attached form a 5 to 7 membered ring containing at least one additional heteroatom selected from O, N or S include, but are not limited to 1- imidazolyl, 2-(R8)-l-imidazolyl, 1-pyrazolyl, 3-(R8H-pyrazolyl, 1-triazolyl, 2- triazolyl, 5-(R8)-l-triazolyl, 5-(R8)-2-triazolyl, 5-(R8)-l-tetrazolyl, 5-(R8)-2-tetrazolyl, 1-tetrazolyl, 2-tetrazloyl, morpholinyl, piperazinyl, 4-(Rs)-l- piperazinyl, or pyrrolyl ring. Preferred rings when Rio and R 14 in the moiety -NR10R14 together with the nitrogen to which they are attached form a 5 to 7 membered ring containing at least one additional heteroatom selected from O, N or S include, but are not limited to 1- imidazolyl, 1 -pyrazolyl, 1-triazolyl, 2-triazolyl, 1-tetrazolyl, 2-tetrazolyl. morpholinyl, piperazinyl, and pyrrolyl. The respective rings may be additionally substituted, where applicable, on an available nitrogen or carbon by the moiety R7 as described herein for Formula (I). Illustrations of such carbon substitutions includes, but are not limited to, 2-(R7)-l-imidazolyl, 4-(R7)-l-imidazolyl, 5-(R7)-l-imidazolyl, 3-(R7)-l -pyrazolyl, 4-(R7)-l -pyrazolyl, 5-(R7)-l -pyrazolyl, 4-(R7)-2-triazolyl, 5-(R7)-2-triazolyl, 4-(R7)-l-triazolyl, 5-(R7)-l-triazolyl, 5-(R7)-l-tetrazolyl, and 5-(R7)-2-tetrazolyl. Applicable nitrogen substitution by R7 includes, but is not limited to, l-(R7)-2-tetrazolyl, 2-(R7)-l-tetrazolyl, 4-(R7)-l -piperazinyl. Where applicable, the ring can be substituted one or more times by R7.
Preferred groups for NR10R14 which contain a heterocyclic ring are 5-(Ri4)- 1-tetrazolyl, 2-(Ri4)-l-imidazolyl, 5-(Ri4)-2-tetτazolyl, or 4-(R 14)- 1 -piperazinyl.
Preferred rings for R13 include (2-, 4- or 5-imidazolyl), (3-, 4- or 5-pyrazolyl), (4- or 5-triazolyl[ 1,2,3]), (3- or 5-triazolyl[ 1,2,4]), (5-tetrazolyl), (2-, 4- or 5-oxazolyl), (3-, 4- or 5-isoxazolyl), (3- or 5-oxadiazolyl[ 1,2,4]), (2-oxadiazolyl[l,3,4]), (2-thiadiazolyl[ 1,3,4]), (2-, 4-, or 5-thiazolyl), (2-, 4-, or 5-oxazolidinyl), (2-, 4-, or 5-thiazolidinyl), or (2-, 4-, or 5-imidazolidinyl).
When the R7 group is optionally substituted by a heterocyclic ring such as imidazolyl, pyrazolyl, triazolyl, tetrazolyl, or thiazolyl, the heterocyclic ring itself may be optionally substituted by R8 either on an available nitrogen or carbon atom, such as l-(R8)-2-imidazolyl, l-(R8)-4-imidazolyl, l-(R8)-5-imidazolyl, l-(R8)-3-pyrazolyl, l-(R8)-4-pyrazolyl, l-(R8)-5-pyrazolyl, l-(R8)-4-triazolyl, or l-(R8)-5-triazolyl. Where applicable, the ring may be substituted one or more times by Rg.
Preferred are those compounds of the Formula (I) wherein Rj is -CH2- cyclopropyl, -CH2-C5-6 cycloalkyl, -C4-6 cycloalkyl unsubstituted or substituted with an hydroxyl group, tetrahydrofuran-3-yl, (3- or 4-cyclopentenyl), benzyl or -Ci-2 alkyl optionally substituted by 1 or more fluorines, and -(CH2)2-4 OH; R2 is methyl or fluoro-substituted alkyl, and W is alkynyl of 2 to 4 carbon atoms.
Most preferred are those compounds wherein Ri is -CH2-cyclopropyl, cyclopentyl, 3-hydroxycyclopentyl, methyl or CF2H; X is YR2; Y is oxygen; X2 is oxygen; X3 is hydrogen; X4 is hydrogen, R2 is CF2H or methyl, W is 1,3-butadiynyl, and in Z the R8 group is H and the R14 group of Z is R4. Exemplified compound is:
1 ,4-bis- { [c-3-(3-cyclopentyloxy-4-methoxyphenyl)-r- 1 - hydroxymethylcyclohexan]-3-yl } buta- 1 ,3-diyne, and
1 ,4-bis- [ [c-3-(3-cyclopentyloxy-4-methoxyphenyl)-r- 1 - aminomethylcyclohexan]-3-yl } buta- 1 ,3-diyne.
Pharmaceutically acceptable salts of the instant compounds, where they can be prepared, are also intended to be covered by this invention. These salts will be ones which are acceptable in their application to a pharmaceutical use. By that it is meant that the salt will retain the biological activity of the parent compound and the salt will not have untoward or deleterious effects in its application and use in treating diseases.
Pharmaceutically acceptable salts are prepared in a standard manner. The parent compound, dissolved in a suitable solvent is treated with an excess of an organic or inorganic acid, in the case of acid addition salts of a base, or an excess of organic or inorganic base where the molecule contains a COOH for example.
Pharmaceutical compositions of the present invention comprise a pharmaceutical carrier or diluent and some amount of a compound of the formula (I). The compound may be present in an amount to effect a physiological response, or it may be present in a lesser amount such that the user will need to take two or more units of the composition to effect the treatment intended. These compositions may be made up as a solid, liquid or in a gaseous form. Or one of these three forms may be transformed to another at the time of being administered such as when a solid is delivered by aerosol means, or when a liquid is delivered as a spray or aerosol. The nature of the composition and the pharmaceutical carrier or diluent will, of course, depend upon the intended route of administration, for example parenterally, topically, orally or by inhalation.
For topical administration the pharmaceutical composition will be in the form of a cream, ointment, liniment, lotion, pastes, aerosols, and drops suitable for administration to the skin, eye, ear, or nose.
For parenteral administration the pharmaceutical composition will be in the form of a sterile injectable liquid such as an ampule or an aqueous or non-aqueous liquid suspension.
For oral administration the pharmaceutical composition will be in the form of a tablet, capsule, powder, pellet, atroche, lozenge, syrup, liquid, or emulsion.
When the pharmaceutical composition is employed in the form of a solution or suspension, examples of appropriate pharmaceutical carriers or diluents include: for aqueous systems, water, for non-aqueous systems, ethanol, glycerin, propylene glycol, corn oil, cottonseed oil, peanut oil, sesame oil, liquid parafins and mixtures thereof with water, for solid systems, lactose, kaolin and mannitol; and for aerosol systems, dichlorodifluoromethane, chlorotrifluoroethane and compressed carbon dioxide. Also, in addition to the pharmaceutical carrier or diluent, the instant compositions may include other ingredients such as stabilizers, antioxidants, preservatives, lubricants, suspending agents, viscosity modifiers and the like, provided that the additional ingredients do not have a detrimental effect on the therapeutic action of the instant compositions.
The pharmaceutical preparations thus described are made following the conventional techniques of the pharmaceutical chemist as appropriate to the desired end product. In these compositions, the amount of carrier or diluent will vary but preferably will be the major proportion of a suspension or solution of the active ingredient. When the diluent is a solid it may be present in lesser, equal or greater amounts than the solid active ingredient Usually a compound of formula I is administered to a subject in a composition comprising a nontoxic amount sufficient to produce an inhibition of the symptoms of a disease in which leukotrienes are a factor. Topical formulations will contain between about 0.01 to 5.0% by weight of the active ingredient and will be applied as required as a preventative or curative agent to the affected area. When employed as an oral, or other ingested or injected regimen, the dosage of the composition is selected from the range of from 50 mg to 1000 mg of active ingredient for each administration. For convenience, equal doses will be administered 1 to 5 times daily with the daily dosage regimen being selected from about 50 mg to about 5000 mg.
No unacceptable toxicological effects are expected when these compounds are administered in accordance with the present invention.
The following examples are set forth to illustrate the invention. These examples are not intended to limit the scope of the invention in any manner or fashion. Reference is made to the claims for what is reserved to the inventor hereunder. Methods Of Preparation Synthetic Scheme(s) With Textual Description
Compounds of Formula (I), wherein W is a 1,3-butadiyne and wherein A and B represent Z as defined in relation to Formula (I) or a group convertible to Z and wherein X4 represents X4 as defined in relation to Formula (I) or a group convertible to X4, may be prepared by the processes disclosed herein which comprise, for example, coupling of a molecule of the Formula 1 -Scheme 1 with a molecule of the Formula 2- Scheme 1 using an appropriate metal salt, such as cupric acetate, in a suitable solvent such as DMF or pyridine, or a combination, such as pyridine/methanol/water, as in the method of Eglington and Galbraith (J. Chem. Soc., 1959, 889), to provide a compound of the Formula 3- Scheme 1.
f*rfιtlft*nfl 1
Figure imgf000016_0001
a) Cu(OAc )2n.20, D F or C 5HSN
Reduction of a compound of the Formula (I), wherein W is a 1,3-butadiyne and wherein Z represents Z as defined in relation to Formula (I) or a group convertible to Z and wherein X4 represents X4 as defined in relation to Formula (I) or a group convertible to X4, to a compound of the Formula (I) wherein W is a fully saturated hydrocarbon chain (i.e., n-butyl) may be accomplished using, e.g., palladium metal according to the method of Tedeschi (J. Org. Chem., 1962, 27, 2398), or, e.g., platinum oxide according to the method of Jutz (Ber., 1958, 91, 1867) or that of Suzuki and Kurosawa (Chem. Lett., 1980, 1177). Reduction of a compound of the Formula (I), wherein W is a 1,3-butadiyne and wherein Z represents Z as defined in relation to Formula (I) or a group convertible to Z and wherein X4 represents X4 as defined in relation to Formula (I) or a group convertible to X4, to provide a compound of the Formula 0) wherein W is a 1,3-butadiene may be accomplished using, e.g., the hydroboration-protonolysis procedure of Zweifel and Polston (J. Am. Chem. Soc., 1970, 92, 4068), or, e.g., the hydroalumination-protonolysis procedure of Zweifel et al. (Synthesis, 1977, 52).
Alternatively, compounds of the Formula (1), wherein W, X4 and Z represent W, X4 and Z as defined in relation to Formula (I) or a group convertible to W, X4 or Z, may be prepared from the corresponding ketones as, e.g., compound 1- Scheme 2. by the synthetic procedures described in United States patent applications 08/131054 and PCT application PCT/US94/10816 ; syntheses of such ketone starting materials are described in co-pending U.S. applications 08/130215 filed 01 October 1993 and PCT/US94/10815 filed 23 September 1994 or co-pending USSN 08/130213 and PCT application PCT/US94/10767 filed on 01 October 1993 and 23 September 1994 respectively.
Scheme g
Figure imgf000017_0001
Depending upon the exact nature of the Z and X4 groups of the compounds of the Formula (I), the Zand X4 groups may require protection during the coupling and or reductive steps described herein, followed by deprotection, to provide the Formula (I) compound, as in processes described in co-pending U.S. application filed on even date herewith and identified as P50301; such protective groups are well known to those skilled in the art (See: Greene, T. and Wuts, P.G.M., Protecting Groups in Organic Synthesis, 2nd Ed., John Wiley and Sons, New York, 1991.)
Preparation of the remaining compounds of the Formula (I) may be accomplished by procedures analogous to those described above and in the Examples, infra. It will be recognized that compounds of the Formula (I) may exist in distinct diastereomeric forms possessing distinct physical and biological properties; such isomers may be separated by standard chromatographic methods. Experimental Examples
Example 1 Preparation of 1.4-to-f rc-3-(3-cyclopentyloxy-4-methoxyphenyl -l- hvdroxvmethvlcvclohexanl-3-vnhuta-l .3-divne A suspension of \,4-bis-{ [methyl c-3-(3-cyclopentyloxy-4-methoxyphenyl)-r- 1-cyclohexane carboxylate]-3-yl}buta-l,3-diyne (0.35 g, 0.52 mmol, prepared as described in co-pending U.S. application identified as P50298 and filed on even date herewith) in tetrahydrofuran (3.0 mL) with methanol (0.025 mL) and lithium borohydride (0.04 g, 1.56 mmol) is stirred overnight at room temperature under an argon atmosphere. The reaction mixture is partitioned between methylene chloride and acidic water, is extracted three times, is dried (magnesium sulfate) and is evaporated. Purification by flash column chromatography provides the product
Example 2 Preparation of 1.4-fei.y-(rr-3-(3-cvclopentvloxv-4-methoxvphenvlVr-l- aminomcthvlcvclohcxan.- -vl lhuta-1.3-divne A solution of l,4-t is-{[c-3-(3-cyclopentyloxy-4-methoxyphenyl)-r-l- hydroxymethylcyclohexan]-3-yl)buta-l,3-diyne (0.11 g, 0.16 mmol) in tetrahydrofuran (2 mL) under an argon atmosphere is treated with triphenylphosphine (0.08 g, 0.32 mmol) , phthalimide (0.04 g, 0.32 mmol) and then diethylazodicarboxylate (0.06 mL, 0.32 mmol) is added dropwise. The reaction flask is covered with foil and the mixture is stirred at room temperature for 30 h. The solvent is evaporated and the residue is purified by flash column chromatography, to provide the product phthalimide, which is dissolved in ethanol (0.5 mL) under an argon atmosphere and is stirred with hydrazine hydrate (0.16 mL, 0.3 mmol) for 3 days. The precipitate is removed by filtration, the filtrate is applied to a silica column and the product is eluted.
UTILITY EXAMPLES
EXAMPLE A Inhihitnrv effect of compounds of Formula (I. on in vitro TNF production bv human mpnocyteg
The inhibitory effect of compounds of Formula (I) on in vitro TNF production by human monocytes may be determined by the protocol as described in Badger et al, EPO published Application 0411 754 A2, February 6, 1991, and in Hanna, WO 90/15534, December 27, 1990. EXAMPLE B
Two models of endotoxic shock have been utilized to determine in vivo TNF activity for the compounds of Formula (I). The protocol used in these models is described in Badger et al, EPO published Application 0411 754 A2, February 6, 1991, and in Hanna, WO 90/15534, December 27, 1990. The compound of Example 1 herein demonstrated a positive in vivo response in reducing serum levels of TNF induced by the injection of endotoxin.
EXAMPLE C Isolation of PDE Isozvmes
The phosphodiesterase inhibitory activity and selectivity of the compounds of Formula (I) can be determined using a battery of five distinct PDE isozymes. The tissues used as sources of the different isozymes are as follows: 1) PDE lb, porcine aorta; 2) PDE lc, guinea-pig heart; 3) PDE m, guinea-pig heart; 4) PDE IV, human monocyte; and 5) PDE V (also called "la"), canine trachealis. PDEs la, lb, lc and III are partially purified using standard chromatographic techniques [Torphy and Cieslinski, Mol. Pharmacol., 37:206-214, 1990]. PDE IV is purified to kinetic homogeneity by the sequential use of anion-exchange followed by heparin-Sepharose chromatography [Torphy et al, J. Biol. Chem., 267:1798-1804, 1992].
Phosphodiesterase activity is assayed as described in the protocol of Torphy and Cieslinski, Mol. Pharmacol., 37:206-214, 1990. Positive ICso's in the nanomolar to μM range for compounds of the workings examples described herein for Formula (I) have been demonstrated.

Claims

What is claimed is
1. A compound of Formula (I) :
wherein:
Rl is independently selected from -(CR4R5)nC(O)O(CR4R5)mR6.
-(CR4R5)nC(O)NR4(CR4R5)mR6, -(CR4R5)nO(CR4R5)mR6, or -(CR4R5)rR6 wherein the alkyl moieties is unsubstituted or substituted with one or more fluorines; m is 0 to 2; n is 1 to 4; r is 0 to 6;
R4 and R5 are independently selected from hydrogen or C 1-2 alkyl; R6 is independently selected from hydrogen, methyl, hydroxyl, aryl, halo substituted aryl, aryloxyCi-3 alkyl, halo substituted aryloxyCi-3 alkyl, indanyl, indenyl, C7- 11 polycycloalkyl, tetrahydrofuranyl, furanyl, tetrahydropyranyl, pyranyl, tetrahydrothienyl, thienyl, tetrahydrothiopyranyl, thiopyranyl, C3-6 cycloalkyl, or a C4- 6 cycloalkyl containing one or two unsaturated bonds, wherein the cycloalkyl or heterocyclic moiety is unsubstituted or substituted by 1 to 3 methyl groups, one ethyl group, or an hydroxyl group; provided that: a) when R6 is hydroxyl, then m is 2; or b) when R6 is hydroxyl, then r is 2 to 6; or c) when R6 is 2-tetrahydropyranyl, 2-tetrahydrothiopyranyl, 2-tetrahydrofuranyl, or 2-tetrahydrothienyl, then m is 1 or 2; or d) when R6 is 2-tetrahydropyranyl, 2-tetrahydrothiopyranyl,
2-tetrahydrofuranyl, or 2-tetrahydrothienyl, then r is 1 to 6; c) when n is 1 and m is 0, then R6 is other than H in -(CR4R5)nO(CR4R5)mR6; X is independently selected from YR2, fluorine, NR4R5, or formyl amine;
Y is independently selected from O or S(O)m'; m' is O, l, or 2;
X2 is independently selected from O or NRs; X3 is independently selected from hydrogen or X;
R2 is independently selected from the group consisting of -CH3 and -CH2CH3 optionally substituted by 1 or more fluorines; s is 0 to 4; W is alkyl of 2 to 6 carbons, alkenyl of 2 to 6 carbon atoms or alkynyl of 2 to 6 carbon atoms;
Z is independently CRδR8θRl4, CR8R8OR15, CRδRδSRl4, CR8R8SR15, CR8R8S(O)m'R7, CR8R8NRlθRl4, CRδRδNRlθS(O)2NRiθRl4, CR8R8NRlθS(O)2R7, CR8R8NRlθC(Y')Rl4, CR8R8NRlθC(O)OR7, CR8R8MRlθC(Y,)NRιoRl4, CR8R8NRlθC(NCN)NRlθRl4, CR8R8NRioC(CR4NO2)NRioRl4, CR8R8 RlθC(NCN)SR9,
CR8R8NRioC(CR4NO2)SR9, CRδ 8C(O)ORi4, CR8R8C(Y')NRιoRl4, CR8R8C(NRiθ)NRιoRl4. CRδRδCN, CR8R8(tetrazolyl), CR8R8(imidazolyl), CR8R8(imidazolidinyl), CR8R8(pyrazolyl), CR8R8(thiazolyl), CR8R8( hiazolidinyl), CR8R8(oxazolyl), CR8R8(oxazolidinyl), CR8R8( riazolyl), CR8R8(isoxazolyl), CR8R8(oxadiazolyl), CR8R8(thiadiazolyl), CR8R8(morpholinyl), CRδRδCpipeπdinyl), CR8R8(piperazinyl), CRδRδΦyrrolyl), CRδR8C(NORδ)Rl4, CRδRδC(NORi4)Rδ, CRδRδNRlθC(NRiθ)SR9, CRδRδ RlθC(NRιo)NRiθRi4, CR8R8NRlθC(O)C(O)NRiθRl4, or CRδRδ Rl()C(O)C(O)ORl4; X5 is H, R9, ORδ, CN, C(O)Rδ, C(O)ORδ, C(O)NRδRδ, or NRδRδ; X4 is independently H, R9, ORδ, CN, C(O)R8, C(O)ORδ, C(O)NRδR8, or
NR8R8;
Y' is independendy selected from O or S;
R7 is -(CR4R5)qRl2 or Cj.g alkyl wherein the R12 or C\.^ alkyl group is unsubstituted or substituted one or more times by methyl or ethyl unsubstituted or substituted by 1-3 fluorines, -F, -Br, -Cl, -NO2, -NRJORI 1, -C(O)R8, -C Rδ, -O(CH2)qRδ, -CN, -C(O)NRιoRl l, -O(CH2)qC(O)NRιoRl l, -O(CH2)qC(O)R9, -NRιoC(O)NRιoRl l, -NRlθC(O)Rn, -NRiθC(O)OR9, -NRiθC(O)Ri3, -C(NRiθ)NRlθRl l, -C(NCN)NRlθRl l, -C(NCN)SR9, -NRiθC(NCN)SR9 , -NRιoC(NCN)NRιoRl l, -NRιoS(O)2R9, -S(0)m'R9. -NRlθC(O)C(O)NRιoRl l, - NRιoC(O)C(O)Riθ, or R13; q is 0, l, or 2;
Rl2 is independently selected from Rj , C3-7 cycloalkyl, (2-, 3- or 4-pyridyl), pyrimidyl, pyrazolyl, (1- or 2-imidazolyl), pyrrolyl, piperazinyl, piperidinyl, morpholinyl, furanyl, (2- or 3-thienyl), quinolinyl, naphthyl, or phenyl; R8 is independently selected from hydrogen or R9;
R9 is independently selected from C-..4 alkyl optionally substituted by one to three fluorines;
RjO is independently selected from ORδ or Ri 1; R 11 is independently selected from hydrogen, or C j .4 alkyl optionally substituted by one to three fluorines; or when Rio and Ri 1 are as NRioRl 1 they may together with the nitrogen form a 5 to 7 membered ring comprised of carbon or carbon and at least one additional heteroatom selected from O, N, or S;
Rl3 is independently selected from oxazolidinyl, oxazolyl, thiazolyl, pyrazolyl, triazolyl, tetrazolyl, imidazolyl, imidazolidinyl, thiazolidinyl, isoxazolyl, oxadiazolyl, or thiadiazolyl, and each of these heterocyclic rings is connected through a carbon atom and
Rj4 is hydrogen or R7; or when Rδ and R14 are as NRδRl4 they may together with the nitrogen form a 5 to 7 membered ring comprised of carbon or carbon and one or more additional heteroatoms selected from O, N, or S;
Rl5 is C(O)Ri4, C(O)NR4Ri4, S(O)2R7, or S(O)2NR4Rl4. or the pharmaceutically acceptable salts thereof.
2. A compound according to claim 1 wherein Ri is -CH2-cyclopropyl, cyclopentyl, 3-hydroxycyclopentyl, methyl or CF2H; X is YR2; Y is oxygen; X2 is oxygen; X3 is hydrogen; X4 is hydrogen, R2 is CF2H or methyl, W is 1,3-butadiynyl, and in Z the Rδ group is H and the R14 group of Z is R4.
3. A compound according to claim 2 which is
1 ,4-bis- { [c-3-(3-cyclopentyloxy-4-methoxyphenyl)-r-l- hydroxymethylcyclohexan] -3-yl } buta- 1 ,3-diyne, or 1 ,4-bis- ( [c-3-(3-cyclopentyloxy-4-methoxyphenyl)-r- 1 - aminomethylcyclohexan]-3-yl } buta- 1 ,3-diyne.
4. A pharmaceutical composition comprising a compound of Formula (I) according to claim 1 and a pharmaceutically acceptable excipient
PCT/US1995/013267 1994-12-23 1995-10-10 1,3,3-(trisubstituted)cyclohexane dimers and related compounds WO1996020160A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP95938251A EP0799185A4 (en) 1994-12-23 1995-10-10 1,3,3-(trisubstituted)cyclohexane dimers and related compounds
JP8520430A JPH10511387A (en) 1994-12-23 1995-10-10 1,3,3- (Trisubstituted) cyclohexane dimers and related compounds

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36318094A 1994-12-23 1994-12-23
US08/363,180 1994-12-23

Publications (1)

Publication Number Publication Date
WO1996020160A1 true WO1996020160A1 (en) 1996-07-04

Family

ID=23429160

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1995/013267 WO1996020160A1 (en) 1994-12-23 1995-10-10 1,3,3-(trisubstituted)cyclohexane dimers and related compounds

Country Status (3)

Country Link
EP (1) EP0799185A4 (en)
JP (1) JPH10511387A (en)
WO (1) WO1996020160A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009151494A1 (en) * 2008-03-06 2009-12-17 Teva Pharmaceutical Industries Ltd. Processes for the preparation of o-desmethylvenlafaxine, free from its dimer impurities
US8063250B2 (en) 2007-11-26 2011-11-22 Teva Pharmaceutical Industries, Ltd. Crystal forms of O-desmethylvenlafaxine fumarate
US8569371B2 (en) 2010-03-29 2013-10-29 Pliva Hrvatska D.O.O. Crystal forms of O-desmethylvenlafaxine fumarate

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2807192A (en) * 1991-10-02 1993-05-03 Smithkline Beecham Corporation Cyclopentane and cyclopentene derivatives with antiallergic antiinflammatory and tumor necrosis factor inhibiting activity
EP0634930A4 (en) * 1992-04-02 1995-02-22 Smithkline Beecham Corporation Compounds useful for treating allergic and inflammatory diseases.

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, Volume 123, issued 1995, CHRISTENSEN S., "Preparation of Cyanocyclohexane Compounds as Tumor Necrosis Factors", Abstract No. 143338; & WO,A,95 09836. *
See also references of EP0799185A4 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8063250B2 (en) 2007-11-26 2011-11-22 Teva Pharmaceutical Industries, Ltd. Crystal forms of O-desmethylvenlafaxine fumarate
WO2009151494A1 (en) * 2008-03-06 2009-12-17 Teva Pharmaceutical Industries Ltd. Processes for the preparation of o-desmethylvenlafaxine, free from its dimer impurities
US8569371B2 (en) 2010-03-29 2013-10-29 Pliva Hrvatska D.O.O. Crystal forms of O-desmethylvenlafaxine fumarate

Also Published As

Publication number Publication date
EP0799185A1 (en) 1997-10-08
EP0799185A4 (en) 1998-03-25
JPH10511387A (en) 1998-11-04

Similar Documents

Publication Publication Date Title
WO1995009836A1 (en) Cyanocyclohexane compounds, compositions, and uses thereof
EP0799182A1 (en) 3,3-(disubstituted)cyclohexan-1-ol dimers and related compounds
EP0799185A1 (en) 1,3,3-(trisubstituted)cyclohexane dimers and related compounds
US5767151A (en) 3,3-(disubstituted) cyclohexan-1-ylidine acetate dimers and related compounds
EP0801567A1 (en) 1,3,3-(trisubstituted)cyclohex-1-ene monomers and related compounds
WO1996019983A1 (en) 4,4-(disubstituted)cyclohexan-1-ylidine acetate dimers and related compounds
AU4590096A (en) 3,3-(disubstituted)cyclohexan-1-ol monomers and related compounds
WO1996020690A2 (en) 3,3-(disubstituted)cyclohexan-1-ylidine acetate monomers and related compounds
EP0799205B1 (en) 1,4,4-(trisubstituted)cyclohex-1-ene derivatives as pde iv- and tnf-inhibitors
WO1996020156A1 (en) 3,3-(disubstituted)cyclohexan-1-carboxylate dimers and related compounds
EP0799031A1 (en) 1,4,4-(trisubstituted)cyclohexane dimers and related compounds
WO1996020174A1 (en) 1,3,3-(trisubstituted)cyclohexane monomers and related compounds
WO1996020161A1 (en) 4,4-(disubstituted)cyclohexan-1-ol dimers and related compounds
EP0802791A1 (en) 3,3-(disubstituted)cyclohexan-1-ylidine acetate dimers and related compounds
WO1996019986A1 (en) 1,4,4-(trisubstituted)cyclohexane monomers and related compounds
WO1996020153A1 (en) 4,4-(disubstituted)cyclohexan-1-one dimers and related compounds
EP0801566A1 (en) 4,4-(disubstituted)cyclohexan-1-ylidine acetate monomers and related compounds
WO1996019994A1 (en) 3,3-(disubstituted)cyclohexan-1-carboxylate monomers and related compounds
WO1996019980A1 (en) 3,3-(disubstituted)cyclohexan-1-one dimers and related compounds
EP1071646A1 (en) Phosphodiesterase isoenzyme denominated 4 (pde 4) inhibiting compounds
WO1996019978A1 (en) 1,3,3-(trisubstituted)cyclohex-1-ene dimers and related compounds
EP0799186A1 (en) 1,4,4-(trisubstituted)cyclohex-1-ene dimers and related compounds

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref country code: US

Ref document number: 1997 860289

Date of ref document: 19970623

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1995938251

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1995938251

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1995938251

Country of ref document: EP